Cytarabine dose for acute myeloid leukemia. - Wikidata - wikimedia - TriplyDB

Cytarabine dose for acute myeloid leukemia.

Cytarabine dose for acute myeloid leukemia.

http://www.wikidata.org/entity/Q34627648

about

Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (APL))An update of current treatments for adult acute myeloid leukemia Fourteenth biannual report of the Cochrane Haematological Malignancies Group--focus on autologous stem cell transplantation in hematological malignancies Progress in acute myeloid leukemia Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.'Acute myeloid leukemia: a comprehensive review and 2016 update'DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches.Poor Prognosis in Acute Myeloid Leukemia Patients with Monosomal Karyotypes Primary refractory acute myeloid leukaemia - in search of better definitions and therapies.Antineoplastic effects of CPPTL via the ROS/JNK pathway in acute myeloid leukemia.Is there a standard induction regimen for patients with AML?Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia.Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis.SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.Acute myeloid leukemia: 2014 update on risk-stratification and management.Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia.Piperlongumine induces apoptotic and autophagic death of the primary myeloid leukemia cells from patients via activation of ROS-p38/JNK pathways.Short-term therapeutic effects of low-dose cytarabine plus surgical resection on elderly patients with trigeminal nerve tumor and safety observation.The treatment of elderly patients with acute myeloid leukemia.Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia Including historical data in the analysis of clinical trials: Is it worth the effort?Redox control of leukemia: from molecular mechanisms to therapeutic opportunities.Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients.The role of transporters in the toxicity of nucleoside and nucleotide analogs.Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.Upfront therapy of acute myeloid leukemia.How to manage high-risk acute myeloid leukemia.High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.

P2860

Q24188096-B3951E16-7389-4B49-81BC-0E1223BD41F4 Q26776396-9AAD6DEE-B636-43C0-8648-D50BEF6F6B16 Q26830130-6AF089B0-44D3-48CE-9629-AFA13EDE91D0 Q27024006-C398BD4D-EEEB-4432-934A-43E766AE2FDB Q27851694-75CA9377-B23D-4E3B-A4D1-41C4EA421FB7 Q28072539-A101BD4B-AE17-4C5E-8FE7-FC407F6C2B49 Q28073970-A98337D6-F9DA-4E07-86AE-94A11CB75EA4 Q30249813-610253A2-9DCE-4D81-AC94-DB246954D3DC Q33716486-6BEB7148-864B-4009-8ECC-5EA9F63F3006 Q33877213-010F71E8-9687-4908-9437-D2450C46E23E Q33889046-6ABCA52A-A81D-403B-B624-35DD4E93F6F8 Q33952411-257217D8-6366-409B-8C84-FFDF11DDF8F0 Q33968321-F9D9F2B9-D8C2-4633-A727-380070DB3299 Q33981864-CA740B1A-E024-4558-9E78-17926121ABA1 Q34205736-ED862EBC-6BC2-4C97-B27B-B133B9F7BD37 Q34317679-D8DBEFB5-BEF9-4D0D-AD91-43248A75AE2F Q34547626-C0826C69-AF9D-42F1-98DD-AC924BA2E66C Q34663691-D56BFC76-0EB0-44B3-BB9D-BA794FC9FD64 Q34665691-AEC267D7-B781-4838-8EF9-BFCFBCB2CFA4 Q35062514-4C67F519-B6E4-4A34-8A30-17453AC1B99D Q35146284-23424F64-A106-4506-B405-759BFD8F201E Q35148199-A85DA264-2736-4438-9EDF-AB1261EB4E9A Q35277528-39BCB4B8-8503-458E-A942-41BAE50ACE68 Q35673578-D36E896A-AE41-445D-AC3E-62F01B367D1D Q35794435-9D439F1C-8B3B-4B7E-81C9-EF7C4691FAEA Q35859437-FA77908B-8103-4810-AB33-7CD457D5EA4D Q36152664-0318E171-0F3F-4E5C-8545-51B3C1C08EDA Q36290737-19293239-A644-43F7-91A1-5E3DB95D944C Q36315895-FC2F62FD-235B-4391-9431-89C1B3B00820 Q36646486-7D3CF44E-F006-4974-86C0-159482B57F7C Q36680199-FFCF4049-1956-40F2-A97F-E4966D85F1DF Q36805563-0BC9152D-EB36-4F3A-8F69-CE780C37A3B2 Q36921993-97A678BE-E59D-4404-92C2-3BB333659BDE Q37079033-F83015C4-DDB3-444F-8B76-2630A8588B98 Q37372832-5E2BA512-29C8-4313-89F5-7D6B6E78DADF Q37624593-85EAAF13-B6EF-49A5-A8F4-55BD37D6722A Q37625632-53E0B167-A126-4B42-B2B4-79B37D5AAEF7 Q37897183-3EE14883-A512-46A3-B1F6-51A7D882F1EE Q37960820-5358F736-426A-487B-8B3C-27CDCB60A645 Q38023520-3376DD33-3243-46FD-8034-58A806396FEF

P2860

Cytarabine dose for acute myeloid leukemia.

http://www.wikidata.org/entity/Q34627648

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Cytarabine dose for acute myeloid leukemia.

@ast

Cytarabine dose for acute myeloid leukemia.

@en

Cytarabine dose for acute myeloid leukemia.

@nl

type

label

Cytarabine dose for acute myeloid leukemia.

@ast

Cytarabine dose for acute myeloid leukemia.

@en

Cytarabine dose for acute myeloid leukemia.

@nl

prefLabel

Cytarabine dose for acute myeloid leukemia.

@ast

Cytarabine dose for acute myeloid leukemia.

@en

Cytarabine dose for acute myeloid leukemia.

@nl

P1433

Q34627648-50A48EB5-BFD2-4328-BCE9-D2757D156175

P1476

Q34627648-DC5E4CD3-9F97-4765-BB17-BDE3E3B798E1

P2093

Q34627648-0CCB48A4-7FEE-4060-B724-7791EAD6850D

Q34627648-109062BA-722B-4DC2-B562-CAE3CDE84D94

Q34627648-3480CB3B-636B-45CC-9FE4-9F87463443F7

Q34627648-363CB444-4541-4CA8-80E5-E8D95D72E5A7

Q34627648-5E7E8878-8390-4FCD-9386-E5F6CD1C688F

Q34627648-7DBF4D2B-6D63-499D-9DBE-9830FA2F7DE2

Q34627648-827EEC2F-4374-464B-A0BF-3B1F93A53A48

Q34627648-84BAAFA6-BC88-4D02-85D2-8725BA402890

Q34627648-99875D87-E73E-4CA7-9F73-85DC5D2464BE

Q34627648-A2D3B0CD-C87B-42B8-A411-684AB4530173

P304

Q34627648-70078B75-0423-4E64-B661-8B4E2FD1D810

P31

Q34627648-6C0B8BE1-06EB-4926-9A0A-BABBF21694EE

P356

Q34627648-08D4B1BA-D26B-4809-AF30-6AD769AA2110

P407

Q34627648-4056CDE8-5529-4561-B377-0294C915A424

P433

Q34627648-23D13DAC-5700-4A8B-B06C-25165B3549DF

P478

Q34627648-6E7529B7-5D39-4256-A1DA-BD78E753D6E9

P50

Q34627648-519CA65E-D9B5-4279-966D-DD36F28FDB47

Q34627648-BB64ABBC-89F7-437C-96CD-4EB66FDE33DB

Q34627648-E254ABB4-A796-4BB7-ABAD-2A51478171C4

P577

Q34627648-43166417-9D96-4B8F-800C-B9C2CD2916D3

P5875

Q34627648-63B1C8C0-39D5-42DD-91C8-7584991587B4

P698

Q34627648-DE6366D1-1858-4D74-881D-C3970BF6FA1F

P921

Q34627648-7F5C0078-6F7A-4F56-9298-2C9BB93A0F91

P356

P1433

The New England Journal of Medicine

P1476

Cytarabine dose for acute myeloid leukemia.

@en

P2093

Augustin Ferrant

http://www.w3.org/2001/XMLSchema#string

Bart J Biemond

http://www.w3.org/2001/XMLSchema#string

Carlos Graux

http://www.w3.org/2001/XMLSchema#string

Dutch-Belgian Cooperative Tria ...... rch (SAKK) Collaborative Group

http://www.w3.org/2001/XMLSchema#string

Edo Vellenga

http://www.w3.org/2001/XMLSchema#string

Georgine E de Greef

http://www.w3.org/2001/XMLSchema#string

Gert J Ossenkoppele

http://www.w3.org/2001/XMLSchema#string

Harry C Schouten

http://www.w3.org/2001/XMLSchema#string

Johan Maertens

http://www.w3.org/2001/XMLSchema#string

Leo F Verdonck

http://www.w3.org/2001/XMLSchema#string

P304

1027-1036

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1010222

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

364

http://www.w3.org/2001/XMLSchema#string

P50

Pieter Sonneveld

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50407979

http://www.w3.org/2001/XMLSchema#string

P698

21410371

http://www.w3.org/2001/XMLSchema#string

P921